covi-amg
mAbexperimentalCOVID-19
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04584697)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04734860 | Phase 2 | Apr 30, 2021 | Sorrento Therapeutics, Inc. |
| NCT04738175 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2021 | Sorrento Therapeutics, Inc. |
| NCT04771351 | Phase 2 | Apr 30, 2021 | Sorrento Therapeutics, Inc. |
| NCT04584697 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Sorrento Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sorrento Therapeutics, Inc. | For profit | 4 | 4 | 1 | 2020 |
1 organizations
Page 1 / 1